MICHAEL S WYZGA
CIK 1201256 · Chief Executive Officer · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$31.5K
Companies
11
Total Filings
66
Lifetime Open-Market Net
-$6.56M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVRD | Director | — | $2.44 | — | $0 | 2 | 2026-06-11 |
| MREO | Director | 25,050 | $0.31 | $7.8K | $0 | 4 | 2026-02-27 |
| XFOR | Director | 5,555 | $3.93 | $21.8K | $29.9K | 10 | 2026-01-05 |
| IVVD | Director | — | $0.59 | — | $0 | 1 | 2023-05-25 |
| LogicBio Therapeutics, Inc. (LOGC) Delisted | Director | 0 | $7.06 | $0 | $0 | 7 | 2022-11-17 |
| Invivyd, Inc. (ADGI) Delisted | Director | — | $4.64 | — | $0 | 2 | 2022-06-24 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 2,558 | $104.91 | $268.4K | -$3.68M | 12 | 2021-03-02 |
| AKBA | Director | 1,500 | $1.27 | $1.9K | $25.5K | 5 | 2018-06-15 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Director | — | — | — | $0 | 4 | 2014-08-05 |
| GENZ | Executive VP and CFO | 0 | $38.46 | $0 | -$2.94M | 8 | 2011-04-06 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | Director | — | $10.12 | — | $0 | 4 | 2009-07-02 |
Recent Filings · Page 7 of 7
66 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-06-13 | Altus Pharmaceuticals Inc. (ALTU) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-27 | GENZ | Grant (A) | — | $0 | EDGAR |
| 2007-12-18 | GENZ | Mixed | — | -$265.6K | EDGAR |
| 2007-06-28 | Altus Pharmaceuticals Inc. (ALTU) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-05-29 | GENZ | Grant (A) | — | $0 | EDGAR |
| 2007-02-05 | Altus Pharmaceuticals Inc. (ALTU) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 61–66 of 66
Prev
Page 7 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.